Literature DB >> 3767551

Eosinophilic vasculitis leading to amaurosis fugax in a patient with acquired immunodeficiency syndrome.

N D Schwartz, Y T So, H Hollander, S Allen, K H Fye.   

Abstract

A 49-year-old bisexual man with generalized lymphadenopathy and antihuman T lymphocyte virus, type III, (HTLV-III) antibodies presented with recurrent, unilateral amaurosis fugax. A temporal artery biopsy specimen showed eosinophilic vasculitis. The patient then developed acquired immunodeficiency syndrome with Kaposi's sarcoma. We describe this patient because of the unusual association of large vessel vasculitis and acquired immunodeficiency syndrome.

Entities:  

Mesh:

Year:  1986        PMID: 3767551

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  5 in total

1.  Cerebral venous thrombosis and dual primary infection with human immunodeficiency virus and cytomegalovirus.

Authors:  M C Meyohas; E Roullet; C Rouzioux; A Aymard; B Pelosse; M Eliasceiwicz; J Frottier
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

2.  Temporal artery vasculitis in young: a report of two cases.

Authors:  Kumar Pannagasayanam Dinesh; Adekunle Owolabi; Lisa Dwyer-Joyce; Patrick M Cronin; Barry M Schimmer; Gyi P Mo
Journal:  Rheumatol Int       Date:  2009-08-21       Impact factor: 2.631

3.  ¹⁸F-FDG PET/CT in HIV-related central nervous system pathology.

Authors:  Scarlett Lewitschnig; Keerti Gedela; Martina Toby; Ranjababu Kulasegaram; Mark Nelson; Michael O'Doherty; Gary J R Cook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-18       Impact factor: 9.236

Review 4.  Neurological complications in AIDS.

Authors:  P A Fischer; W Enzensberger
Journal:  J Neurol       Date:  1987-06       Impact factor: 4.849

5.  Development of Eosinophilic Temporal Arteritis and Digital Ischemia in a Patient with Hypereosinophilic Syndrome.

Authors:  Kayo Ishii; Takahiro Mizuuchi; Yusuke Yamamoto; Hiroaki Mori; Mayu Tago; Eri Kato; Haeru Hayashi; Koichiro Tahara; Tetsuji Sawada
Journal:  Intern Med       Date:  2020-02-26       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.